TempraMed Technologies Ltd, a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, announced that it has been granted an additional allowed patent in South Korea, issued under Korean Patent Application No. 10-2021-7011422.

Newly granted patent protects TempraMed Technologies' VIVI Box proprietary, hassle-free thermal-insulation system and smart-monitoring architecture. It expands the company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics. It enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia's premium refrigeration market.

The patent covers, among other features, the company's new product category, VIVI Box, a consumer-focused medical-storage system engineered to keep temperature-sensitive medications safe within domestic refrigerators. The system prevents freezing, stabilizes medication temperatures, and maintains a secure 8°C environment for up to 24 hours without external power. VIVI Box provides uninterrupted protection during routine use, travel, transportation, or unexpected power outages. Designed to support fast-growing medication categories including insulin, GLP-1 therapies, biologics, and other specialty drugs, VIVI Box offers a dependable, reusable solution that bridges the gap between pharmacy cold-chain requirements and real-world patient behaviour.

Without limiting the scope of the patent, it includes capabilities such as: Continuous temperature protection during power interruptions or refrigerator temperature fluctuations; A portable, all-day travel solution for users requiring secure on-the-go cold storage; Smart content tracking with cloud-based data integration to support adherence and remote monitoring.

These capabilities position VIVI Box as a differentiated platform at the intersection of home health, smart refrigeration, and the consumer IoT medical-device ecosystem. The invention advances TempraMed Technologies’ strategy to evolve beyond single-injection protection into multi-dose, multi-format medication-storage systems - core components of the company's long-term commercialization plan.

"Being granted this additional patent in South Korea marks an important milestone in our mission to redefine temperature stability and management for medications worldwide," said Ron Nagar, CEO of TempraMed Technologies. "VIVI Box represents the next major step in our strategy to move beyond single-device protection and deliver scalable, multi-medication storage solutions for patients and healthcare systems.

"As more high-value biologics, peptides, GLP-1 therapies, and specialty medications enter the market, the need for safe, compliant, and temperature-stable storage continues to grow dramatically. Combined with our expanding patent portfolio, deep distribution partnerships, and commitment to engineering excellence, TempraMed Technologies is exceptionally well-positioned to lead the next chapter of innovation. We are building a global platform that protects patient health, reduces medication waste, and redefines medications storage standards around the world."

This new patent follows a series of recent milestones for TempraMed Technologies, including exclusive distribution agreements across Israel, Turkey, and major European regions with partners such as Guri A.A.O, Dolfin Saglik, and Salomo Executive. These partnerships expand TempraMed's reach across retail pharmacy chains, HMOs, and healthcare networks.

Together, these achievements support the company's multi-year strategy to scale globally, introduce new product categories, and establish TempraMed Technologies as the worldwide leader in temperature-regulated medication protection and management.